Career Development Awards will be used to support the development of careers in translational pancreatic cancer research by individuals from one of the following categories: 1) clinical fellows in medical oncology, gastroenterology, pathology, or surgery; 2) junior faculty members at the instructor or assistant professor level, either clinical faculty who seek training and an opportunity to establish a career that includes basic science research, or basic science faculty who want additional training or an opportunity to undertake translational research; 3) senior postdoctoral fellows who are at the point of entering the academic ranks and establishing independent research programs; 4) established clinical faculty who require additional training in basic or translational research in order to establish a translational research program. We will support one new candidate in each year of the grant at a level of $87,500 per year for two years ($175,000 total) for each award. $75,000 per year will be provided by matching funds from the UNMC Eppley Cancer Center, and $100,000 will be provided by the SPORE program, so that up to $175,000 total per year is available for this program. Individuals in this program are required to commit substantial effort (a minimum of 40%, and higher percent efforts are strongly encouraged and will receive preferential selection) to SPORE related translational research. Funds can be used for salaries or any other aspect of development (research costs) that are deemed necessary for the candidate to succeed in establishing a translational pancreatic cancer research program. The candidate is required to submit an NIH G or R series grant application during the second year of the award, that is primarily focused on pancreatic cancer research.
| Banerjee, Kasturi; Kumar, Sushil; Ross, Kathleen A et al. (2018) Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett 417:35-46 |
| Wiest, Edwin J; Smith, Heather Jensen; Hollingsworth, Michael A (2018) Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum. Biochem Biophys Res Commun 501:858-862 |
| Chugh, Seema; Barkeer, Srikanth; Rachagani, Satyanarayana et al. (2018) Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. Gastroenterology 155:1608-1624 |
| Jahan, Rahat; Macha, Muzafar A; Rachagani, Satyanarayana et al. (2018) Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-?1/FAK/ERK pathway. Biochim Biophys Acta Mol Basis Dis 1864:2538-2549 |
| Qazi, Asif Khurshid; Siddiqui, Jawed A; Jahan, Rahat et al. (2018) Emerging therapeutic potential of graviola and its constituents in cancers. Carcinogenesis 39:522-533 |
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Qi, Bowen; Crawford, Ayrianne J; Wojtynek, Nicholas E et al. (2018) Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer. Nanomedicine 14:769-780 |
| Goodwin, Justin; Choi, Hyunsung; Hsieh, Meng-Hsiung et al. (2018) Targeting Hypoxia-Inducible Factor-1?/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58:216-231 |
| Coelho, Sílvia Castro; Reis, Daniel Pires; Pereira, Maria Carmo et al. (2018) Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells. Pharmaceutics 10: |
| Krishn, Shiv Ram; Ganguly, Koelina; Kaur, Sukhwinder et al. (2018) Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view. Carcinogenesis 39:633-651 |
Showing the most recent 10 out of 191 publications
